专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017185085A1 BIOMARKERS FOR MONITORING IMMUNE TRANSFORMATION 审中-公开
标题翻译：生物标志物监测免疫转化
公开(公告)号：WO2017185085A1
公开(公告)日：2017-10-26
申请号：PCT/US2017/029111
申请日：2017-04-24
申请人： BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA , THE SCRIPPS RESEARCH INSTITUTE
发明人： GENDELMAN, Howard, E. , MOSLEY, R., Lee , SIUZDAK, Gary , FORSBERG, Erica
IPC分类号： A61K38/19 , C12N5/00 , G01N33/50 , G01N33/68 , G01N33/94
CPC分类号： A61K38/193 , A61K38/2278 , G01N33/505 , G01N33/6896 , G01N33/942 , G01N2800/52
摘要： The present invention provides novel biomarkers for regulatory T cells (Treg) function and Parkinson's disease.
摘要翻译：本发明提供了用于调节性T细胞（Treg）功能和帕金森病的新型生物标志物。

2. 发明申请

WO2015077416A1 METHODS OF REDUCING CORNEAL ENDOTHELIAL CELL LOSS 审中-公开
标题翻译：减少角膜内皮细胞损失的方法
公开(公告)号：WO2015077416A1
公开(公告)日：2015-05-28
申请号：PCT/US2014/066551
申请日：2014-11-20
申请人： MASSACHUSETTS EYE AND EAR INFIRMARY , SCHEPENS EYE RESEARCH INSTITUTE
发明人： YAMAGUCHI, Takefumi , JURKUNAS, Ula , HAMRAH, Pedram
IPC分类号： A61K38/16 , A61P27/02
CPC分类号： A61K38/2278 , A61B3/1025 , A61K9/0048
摘要： Provided herein are methods of reducing corneal endothelial cell loss (e.g., nerve loss-related corneal endothelial cell loss) that include selecting a subject identified as having an eye with reduced numbers of corneal nerves as compared to a reference eye, e.g., an eye of a healthy control, and administering vasoactive intestinal peptide (VIP) or a nucleic acid encoding VIP to the selected subject.
摘要翻译：本文提供减少角膜内皮细胞损失（例如，神经损失相关的角膜内皮细胞损失）的方法，其包括与参考眼相比选择被认为具有减少数量的角膜神经的眼睛的被摄体的受试者，例如眼睛健康对照，以及对所选受试者施用血管活性肠肽（VIP）或编码VIP的核酸。

3. 发明申请

WO2015023890A1 GLYCOSYLATED PACAP/VIP ANALOGUES WITH ENHANCED CNS PENETRATION FOR TREATMENT OF NEURODEGENERATIVE DISEASES 审中-公开
标题翻译：具有增强CNS渗透治疗神经病变性疾病的GLYCOSYLATED PACAP / VIP类似物
公开(公告)号：WO2015023890A1
公开(公告)日：2015-02-19
申请号：PCT/US2014/051143
申请日：2014-08-14
申请人： THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
发明人： POLT, Robin , FALK, Torsten, A E
IPC分类号： A61K38/16 , A61P25/02 , A61K38/00
CPC分类号： A61K38/1709 , A61K38/2278 , C07K2317/21 , C07K2317/41 , C12N5/0619 , G01N33/6896 , G01N2800/2814 , G01N2800/2821
摘要： A glycosylated pleiotropic peptide pituitary adenylate cyclase-activating polypeptide (PACAP) which can both agonize PAC, receptors, causing neuroprotective effects, and antagonize VPAC receptors, causing anti-inflammation in several models of acute neuronal damage and neurodegenerative diseases, including ALS, PA, migraines, and certain forms of dementia, is described. Also described is a method of relieving symptoms of ALS, PA, migraines, and certain forms of dementia, comprising administering to a subject in need thereof an effective amount of a glycosylated PACAP.
摘要翻译：可以同时激发PAC，受体，引起神经保护作用，拮抗VPAC受体的糖基化多效肽垂体腺苷酸环化酶激活多肽（PACAP），在几种急性神经元损伤和神经变性疾病模型中引起抗炎，包括ALS，PA，描述了偏头痛和某些形式的痴呆症。还描述了减轻ALS，PA，偏头痛和某些形式的痴呆症状的方法，包括向有需要的受试者施用有效量的糖基化PACAP。

4. 发明申请

WO2014080162A1 VIP AND AN ALPHA-ADRENERGIC BLOCKER FOR USE IN THE DIAGNOSIS OF ERECTILE DYSFUNCTION AND VASCULAR ISCHAEMIA 审中-公开
标题翻译： VIP和ALPHA-ADRENERGIC阻塞器用于诊断溃疡性功能障碍和血管异位症
公开(公告)号：WO2014080162A1
公开(公告)日：2014-05-30
申请号：PCT/GB2013/000509
申请日：2013-11-21
申请人： MENS HEALTH LTD
发明人： WYLLIE, Mike
IPC分类号： A61K38/22 , A61K45/06 , A61P9/10
CPC分类号： A61K38/2278 , A61K31/417 , A61K45/06 , A61K2300/00
摘要： The present invention provides a method of providing an objective, repeatable measure of the severity of an erectile dysfunction condition comprising: a) the administration in a therapeutically effective amount of a physiological mediator of penile erection, generally a vasoactive intestinal peptide (VIP) and a therapeutically effective amount of an alpha-adrenergic blocker; b) measuring the erectile response; c) grading the severity of the ED condition through the erectile response measurements. There is also provided a method of diagnosing a patient suffering from vascular ischaemia comprising: • identifying an area of the body (typically a limb) exhibiting symptoms of vascular ischaemia; • administering a therapeutically effective amount of a vasoactive intestinal peptide (VIP) and a therapeutically effective amount of an alpha-adrenergic blocker; wherein if the symptoms of vascular ischaemia are alleviated, eliminated or relieved within a predetermined period from administration, the patient is likely to be suffering from vascular ischaemia. The VIP is generally included in a composition having a pH of from around 6 to around 9.
摘要翻译：本发明提供了提供勃起功能障碍病症严重程度的客观可重复测量的方法，包括：a）以治疗有效量的阴茎勃起生理介质（通常为血管活性肠肽（VIP））和治疗有效量的α-肾上腺素能阻滞剂; b）测量勃起反应; c）通过勃起反应测量法评估ED病情的严重程度。还提供了一种诊断患有血管缺血的患者的方法，包括：•鉴定表现血管缺血症状的身体区域（通常为肢体）; •施用治疗有效量的血管活性肠肽（VIP）和治疗有效量的α-肾上腺素能阻滞剂; 其中如果血管局部缺血的症状在给药的预定时间内缓解，消除或缓解，则患者可能患有血管缺血。 VIP通常包括在pH为约6至约9的组合物中。

5. 发明申请

WO2014067879A1 DRUG DELIVERY DEVICE WITH DRUG CONTAINER COMPRISING A SENSOR AND OPTICAL DATA TRANSMISSION SYSTEM 审中-公开
标题翻译：具有包含传感器和光学数据传输系统的药物容器的药物递送装置
公开(公告)号：WO2014067879A1
公开(公告)日：2014-05-08
申请号：PCT/EP2013/072445
申请日：2013-10-25
申请人： SANOFI-AVENTIS DEUTSCHLAND GMBH
发明人： NESSEL, Christian , AUERNHAMMER, Daniel
IPC分类号： A61M5/315 , A61M5/24 , A61M5/145 , A61J1/05 , A61M5/168
CPC分类号： A61M5/172 , A61G2203/32 , A61J1/062 , A61K38/2278 , A61K38/26 , A61K38/28 , A61M5/1456 , A61M5/14566 , A61M5/16854 , A61M5/24 , A61M5/31511 , A61M5/31515 , A61M5/31525 , A61M2005/16863 , A61M2205/15 , A61M2205/3306 , A61M2205/332 , A61M2205/3324 , A61M2205/3331 , A61M2205/3368 , A61M2205/3569 , A61M2205/3592 , A61M2205/50 , A61M2205/8212 , A61M2205/8293 , H04B10/1141 , H04B10/807
摘要： Drug delivery device (1) having a container (2) containing a fluid medicament and sealed on one end with a moveable piston (2.1), the piston comprising an electrically operable sensor (3) for measuring a physical or chemical parameter related to the container (2) and/or fluid medicament therein, wherein the sensor of the piston comprises an optical receiver (3.2) designed to receive optical radiation energy and to transform said optical radiation energy into electrical energy for powering and operating the sensor (3), and an optical emitter (3.4) for communicating with the drug delivery device, and the drug delivery device comprises a control unit (4) comprising optical emitter and receiver (4.2, 4.4) and a signal processing unit (4.5).
摘要翻译：药物输送装置（1）具有包含流体药物的容器（2），并在一端用可移动的活塞（2.1）密封，所述活塞包括用于测量与容器相关的物理或化学参数的电可操作传感器（3）（2）和/或其中的流体药物，其中所述活塞的传感器包括设计成接收光辐射能量并将所述光辐射能量转换成电能以对所述传感器（3）供电和操作的光接收器（3.2），以及用于与药物递送装置通信的光发射器（3.4），药物递送装置包括包括光发射器和接收器（4.2,4.4）和信号处理单元（4.5）的控制单元（4）。

6. 发明申请

WO2013173827A2 METHODS AND COMPOSITIONS FOR INHIBITING DISEASES OF THE CENTRAL NERVOUS SYSTEM 审中-公开
标题翻译：抑制中枢神经系统疾病的方法和组合物
公开(公告)号：WO2013173827A2
公开(公告)日：2013-11-21
申请号：PCT/US2013/041814
申请日：2013-05-20
申请人： BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
发明人： GENDELMAN, Howard, E. , MOSLEY, R., Lee
IPC分类号： A61K38/16
CPC分类号： A61K39/39 , A61K38/1709 , A61K38/193 , A61K38/2278 , A61K39/0005 , A61K2039/555 , A61K2300/00
摘要： Methods and compositions for treating central nervous system diseases and disorders are disclosed.
摘要翻译：公开了治疗中枢神经系统疾病和病症的方法和组合物。

7. 发明申请

WO2013058833A1 COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF 审中-公开
标题翻译：包含碱性磷酸酶和/或NATRIURETIC PEPTIDE的组合物及其使用方法
公开(公告)号：WO2013058833A1
公开(公告)日：2013-04-25
申请号：PCT/US2012/039004
申请日：2012-05-22
申请人： ENOBIA CANADA LIMITED PARTNERSHIP , VANDERBIL T UNIVERSITY , CRINE, Philippe , ELEFTERIOU, Florent
发明人： CRINE, Philippe , ELEFTERIOU, Florent
IPC分类号： A61K39/00 , A61K38/00 , A61P13/06 , C12N9/16
CPC分类号： C07K14/58 , A61K38/16 , A61K38/2278 , A61K38/465 , C07K2319/30 , C12N9/16
摘要： The present invention provides methods, compositions, and kits for the treatment of neurocutaneous syndromes, such as neurofibromatosis type I disorders associated with overactivation of FGFR3, such as achondroplasia; bone or cartilage disorders; or vascular smooth muscle disorders; or for the elongation of bone. Polypeptides having an alkaline phosphatase peptide fused to an Fc domain of an immunoglobulin or a natriuretic peptide fused to an Fc domain of an immunoglobulin can be administered to subjects, e.g., subcutaneously, to treat a neurocutaneous syndromes. The invention also features nucleic acid molecules encoding such polypeptides and the use of the nucleic acid molecules for treating neurocutaneous syndromes.
摘要翻译：本发明提供了用于治疗神经性皮肤综合征的方法，组合物和试剂盒，例如与FGFR3过度活化相关的神经纤维瘤病I型障碍，例如软骨发育不良; 骨或软骨疾病; 或血管平滑肌障碍; 或用于骨的伸长。具有与免疫球蛋白的Fc结构域融合的碱性磷酸酶肽的多肽或与免疫球蛋白的Fc结构域融合的利尿钠肽可以给予受试者，例如皮下，以治疗神经皮肤综合征。本发明还具有编码这种多肽的核酸分子以及核酸分子用于治疗神经皮肤综合征的用途。

8. 发明申请

WO2013030409A1 PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE 审中-公开
标题翻译：用于治疗神经病变疾病的药物组合物
公开(公告)号：WO2013030409A1
公开(公告)日：2013-03-07
申请号：PCT/EP2012/067144
申请日：2012-09-03
申请人： SANOFI-AVENTIS DEUTSCHLAND GMBH , UNIVERSITY OF ULSTER , HESS, Sibylle , HÖLSCHER, Christian , BÖHME, Andrees , MENUT, Agnes , PRADIER, Laurent , TAUPIN, Véronique
发明人： HESS, Sibylle , HÖLSCHER, Christian , BÖHME, Andrees , MENUT, Agnes , PRADIER, Laurent , TAUPIN, Véronique
IPC分类号： A61K38/26 , A61P25/28
CPC分类号： A61K38/2278 , A61K38/26
摘要： The present invention refers to a pharmaceutical composition for use in the treatment of a neurodegenerative disease.
摘要翻译：本发明涉及用于治疗神经变性疾病的药物组合物。

9. 发明申请

WO2012138043A2 THERAPEUTIC COMPOSITION CONTAINING ENDOTHELIN AS AN ACTIVE COMPONENT 审中-公开
标题翻译：含有内皮素作为活性成分的治疗组合物
公开(公告)号：WO2012138043A2
公开(公告)日：2012-10-11
申请号：PCT/KR2011010320
申请日：2011-12-29
申请人： SEOUL NAT UNIV HOSPITAL , LEE EUN JU , KIM HYO SOO
发明人： LEE EUN JU , KIM HYO SOO
IPC分类号： A61K31/19 , A61P9/00 , A61P9/10
CPC分类号： A61K38/2278
摘要： The present invention relates to a composition for preventing or treating ischemic disease comprising endothelin or a nucleotide sequence encoding endothelin as an active ingredient, and more particularly to a composition for preventing or treating ischemic heart disease, myocardial infarction, angina pectoris, lower limb artery ischemia, distal limb ischemia and ischemic cerebrovascular disease, wherein the composition is administered by intramuscular injection. According to the present invention, administering endothelin-1 by intramuscular injection may efficiently inhibit the progress of ischemia, fibrosis and tissue necrosis, and induce angiogenesis, such that it is promising for preventing or treating the ischemic disease.
摘要翻译：本发明涉及用于预防或治疗缺血性疾病的组合物，其包含内皮素或编码内皮素作为活性成分的核苷酸序列，更具体地涉及用于预防或治疗缺血性心脏病，心肌梗死，心绞痛，下肢动脉缺血的组合物，远端肢体缺血和缺血性脑血管疾病，其中所述组合物通过肌内注射施用。根据本发明，通过肌内注射给予内皮素-1可有效抑制缺血，纤维化和组织坏死的进展，并诱导血管发生，从而有希望预防或治疗缺血性疾病。

10. 发明申请

WO2012136369A1 OPHTHALMIC PREPARATIONS BASED ON PACAP (PITUITARY ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE) WHICH RESTORE THE NORMAL VISUAL FUNCTION IN EARLY GLAUCOMA 审中-公开
标题翻译：基于PACAP（活性腺苷酸激活多肽）的OPHTHALMIC制剂，恢复早期GLAUCOMA中的正常视觉功能
公开(公告)号：WO2012136369A1
公开(公告)日：2012-10-11
申请号：PCT/EP2012001514
申请日：2012-04-05
申请人： HMFRA HUNGARY LTD LIABILITY COMPANY , DOMENICI LUCIANO , SANSO' MARCO , GIOVANNINI LUCA
发明人： DOMENICI LUCIANO , SANSO' MARCO , GIOVANNINI LUCA
IPC分类号： A61K9/00 , A61K38/22 , A61K47/36 , A61K47/38
CPC分类号： A61K38/2278 , A61K9/0048 , A61K47/36 , A61K47/38
摘要： The present invention relates to ophthalmic preparations in the form of eyedrops based on PACAP (Pituitary Adenylate Cyclase Activating Polypeptide) which restore the normal visual function in retinal dystrophy/retinopathy and optic neuropathy, with special reference to glaucoma. Said preparations can be administered topically to the intact eye surface, and are useful in the treatment of various forms of retinal dystrophy/retinopathy and optic neuropathy, such as glaucoma.
摘要翻译：本发明涉及基于PACAP（垂体腺苷酸环化酶活化多肽）的眼药水形式的眼用制剂，其恢复视网膜营养不良/视网膜病变和视神经病变中的正常视觉功能，特别是青光眼。所述制剂可以局部施用于完整的眼表面，并且可用于治疗各种形式的视网膜营养不良/视网膜病变和视神经病，如青光眼。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式